PHPS1
(Synonyms: PTP Inhibitor V) 目录号 : GC44637PHPS1是一种细胞通透性、磷酸酪氨酸类似物，能够选择性抑制含Src同源结构域的磷酸酶（SHP2），IC50值为2.1µM，Ki值为0.73µM。
Cas No.:314291-83-3
Sample solution is provided at 25 µL, 10mM.
PHPS1 is a cell permeability, phosphotyrosine analog that selectively inhibits Src-homodomain-containing phosphatases (SHP2) with an IC50 value of 2.1µM and a Ki value of 0.73µM[1]. PHPS1 can inhibit SHP2-dependent cell function and tumor cell line growth[2]. PHPS1 can effectively inhibit TGF-β1-induced epithelial-mesenchymal transition in A549 lung epithelial cells[3]. PHPS1 can alleviate airway inflammation and airway hyperresponsiveness in allergic mice[4].
In vitro, treatment of human tumor cell lines (MDA-MB-435, HCT-15, PC-3, HT-29, NCI-H661 cells) with PHPS1 (30µM) for 6 days inhibited the proliferation and colony formation of human tumor cell lines[5].
In vivo, PHPS1 (3mg/kg) administered intraperitoneally to atherosclerotic (AS) mice for one week reduced the number of atherosclerotic plaques without significantly affecting body weight, serum glucose levels, or lipid metabolism, and inhibited the formation of neointima and the proliferation of smooth muscle cells at the aortic root[6]. PHPS1 (15mg/kg) administered intraperitoneally to pancreatic cancer model mice significantly inhibited tumor growth, with the tumor volume in the monotherapy group reduced by approximately 60% compared to the control group[7].
References:
[1] Ramamoorthy D. Synthesis of small molecule inhibitors targeting signal transduction pathways[J]. 2009.
[2] Kong J, Long Y Q. Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors[J]. RSC Medicinal Chemistry, 2022, 13(3): 246-257.
[3] Liu Y, Guan Y, Shen J, et al. RETRACTED ARTICLE: Shp2 positively regulates cigarette smoke-induced epithelial mesenchymal transition by mediating MMP-9 production[J]. Respiratory Research, 2020, 21(1): 161.
[4] Xu C, Wu X, Lu M, et al. Protein tyrosine phosphatase 11 acts through RhoA/ROCK to regulate eosinophil accumulation in the allergic airway[J]. The FASEB Journal, 2019, 33(11): 11706.
[5] Hellmuth K, Grosskopf S, Lum C T, et al. Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking[J]. Proceedings of the National Academy of Sciences, 2008, 105(20): 7275-7280.
[6] Chen J, Cao Z, Guan J. SHP2 inhibitor PHPS1 protects against atherosclerosis by inhibiting smooth muscle cell proliferation[J]. BMC cardiovascular disorders, 2018, 18(1): 72.
[7] Gomes E G, Connelly S F, Summy J M. Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo[J]. Pancreas, 2013, 42(5): 795-806.
PHPS1是一种细胞通透性、磷酸酪氨酸类似物，能够选择性抑制含Src同源结构域的磷酸酶（SHP2），IC50值为2.1µM，Ki值为0.73µM[1]。PHPS1能够抑制SHP2依赖的细胞功能及肿瘤细胞系的生长[2]。PHPS1能够有效抑制TGF-β1 诱导的肺上皮A549细胞的上皮-间质转化[3]。PHPS1能减轻过敏小鼠的气道炎症和气道高反应性[4]。
在体外，PHPS1（30µM）处理人肿瘤细胞系（MDA-MB-435、HCT-15、PC-3、HT-29、NCI-H661细胞）6天，抑制了人肿瘤细胞系的增殖和集落形成[5]。
在体内，PHPS1（3mg/kg）通过腹腔注射治疗动脉粥样硬化（AS）小鼠1周，减少了小鼠动脉粥样硬化斑块的数量，且对体重、血清葡萄糖水平或脂质代谢无显著影响，抑制了主动脉根部的新生内膜的形成和平滑肌细胞的增殖[6]。PHPS1（15mg/kg）通过腹腔注射治疗胰腺癌模型小鼠，显著抑制了肿瘤生长，单药治疗组小鼠的肿瘤体积较对照组减少了约60%[7]。
| Cell experiment [1]: | |
Cell lines | MDA-MB-435、HCT-15、PC-3、HT-29、NCI-H661、Caki-1 cells |
Preparation Method | Cells were treated with a solvent control or 30µM PHPS1 for 6 days. Cell count/standard deviation was determined using a standardized MTT assay. The overall status of these cell lines (untreated) was analyzed by Western blotting using a Shp2-specific antibody. |
Reaction Conditions | 30µM; 6 days |
Applications | PHPS1 inhibits the growth of tumor cells in a Shp2-dependent manner. |
| Animal experiment [2]: | |
Animal models | Ldlr−/− (005061) mice |
Preparation Method | 5 mice were housed in a cage on a 12-h light/dark cycle with free access to water and food. The animals received a high-fat diet containing 1.25% cholesterol for 4 weeks. PHPS1 was dissolved in saline with 0.5% DMSO. 30 mice were randomly divided into three groups: an Atherosclerosis (AS) group, an AS+Vehicle group and an AS+PHPS1 group. Mice in the AS+PHPS1 group received an intraperitoneal (i.p.) injection of 3mg/kg PHPS1 every day during the last week on the high-fat diet, and those in the AS+Vehicle group received an equal volume of saline with 0.5% DMSO on the same days. |
Dosage form | 3mg/kg;7 days; i.p. |
Applications | PHPS1 treatment significantly reduced the atherosclerotic plaque area and inhibited the formation of atherosclerotic plaques. PHPS1 treatment inhibited the proliferation of vascular smooth muscle cells. |
References: | |
| Cas No. | 314291-83-3 | SDF | |
| 别名 | PTP Inhibitor V | ||
| 化学名 | 4-[2-[1,5-dihydro-3-(4-nitrophenyl)-5-oxo-1-phenyl-4H-pyrazol-4-ylidene]hydrazinyl]-benzenesulfonic acid | ||
| Canonical SMILES | O=C1N(C2=CC=CC=C2)N=C(C3=CC=C([N+]([O-])=O)C=C3)/C1=N\NC4=CC=C(S(O)(=O)=O)C=C4 | ||
| 分子式 | C21H15N5O6S | 分子量 | 465.4 |
| 溶解度 | 5mg/mL in DMSO, or in DMF | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1487 mL | 10.7434 mL | 21.4869 mL |
| 5 mM | 429.7 μL | 2.1487 mL | 4.2974 mL |
| 10 mM | 214.9 μL | 1.0743 mL | 2.1487 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet